Edgar Filing: HEIDEN WILLIAM K - Form 4

HEIDEN WILLIAM K						
Form 4 May 16, 2012						
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						PPROVAL 3235-0287
Section 16. Form 4 or Form 5 Filed	pursuant to S 17(a) of the 1	F CHANGES IN I SECUR Section 16(a) of the Public Utility Hold of the Investment	BENEFICIAL O ITIES e Securities Excha ling Company Act	nge Act of 1934, t of 1935 or Sectio	Expires: Estimated burden hou response	urs per
(Print or Type Responses)						
1. Name and Address of Reporting Person <u>*</u> HEIDEN WILLIAM K		2. Issuer Name and Ticker or Trading Symbol AMAG PHARMACEUTICALS		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)		
(Last) (First) C/O AMAG PHARMACEUTICALS, HAYDEN AVENUE	(Middle) INC.,, 100	INC. [AMAG] 3. Date of Earliest Transaction (Month/Day/Year) 05/14/2012		X Director 10% Owner X Officer (give title Other (specify below) below) President & CEO		
(Street) LEXINGTON, MA 0242	Filed(Mc		te Original)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State)	(Zip)	Table I - Non-D	erivative Securities A		f. or Beneficia	llv Owned
1.Title of 2. Transaction I Security (Month/Day/Ye (Instr. 3)		ed 3. Date, if Transaction Code	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or	5. Amount of Securities D Beneficially (Owned (Following (Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Report on a separate	e line for each cl	ass of securities benefi				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: HEIDEN WILLIAM K - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	ate	7. Title and A Underlying S (Instr. 3 and 4	ecurities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Stock Option (Right to Buy)	\$ 12.99	05/14/2012		A	300,000	<u>(1)</u>	05/14/2022	Common Stock	300,00
Restricted Stock Unit	(2)	05/14/2012		А	100,000	(3)	(3)	Common Stock	100,00

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
HEIDEN WILLIAM K C/O AMAG PHARMACEUTICALS, INC., 100 HAYDEN AVENUE LEXINGTON, MA 02421	Х		President & CEO	
Signatures				

/s/Frank Thomas,	05/16/2012
Attorney-in-Fact	03/10/2012

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option vests and becomes exercisable in four equal annual installments beginning on May 14, 2013.
- (2) Each restricted stock unit represents a contingent right to receive one share of AMAG Pharmaceuticals, Inc. common stock.
- (3) The restricted stock units vest in four equal annual installments beginning on May 14, 2013.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.